Biomarin Pharmaceutical Inc (BMRN)

neg -2.33
Today's Range: 97.17 - 100.95 | BMRN Avg Daily Volume: 1,255,900
Last Update: 01/28/15 - 4:00 PM EST
Volume: 1,288,734
YTD Performance: 10.15%
Open: $100.58
Previous Close: $99.58
52 Week Range: $55.04 - $100.50
Oustanding Shares: 147,465,546
Market Cap: 14,674,296,482
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 10
Moderate Buy 1 1 1 1
Hold 3 4 4 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.47 1.56 1.56 1.69
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -113.08
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-113.08 0.00 26.06
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
20.91% 44.30% 177.77%
Revenue 9.50 0.46 0.13
Net Income 0.00 -1.86 0.00
EPS 0.00 -1.64 0.00
Earnings for BMRN:
Revenue 0.55B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $-0.59 $-0.62 $-1.05 $-2.07
Number of Analysts 9 4 11 11
High Estimate $-0.52 $-0.53 $-0.96 $-0.73
Low Estimate $-0.65 $-0.82 $-1.12 $-2.93
Prior Year $-0.27 $-0.27 $-0.76 $-1.05
Growth Rate (Year over Year) -118.93% -127.78% -38.04% -97.57%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
These are surefire indications of a bountiful tape.
Liquidity is crucial to maintaining trust in the system.
Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.
Stocks, like sports, are unfair sometimes. This is one of those times.
As 2014 winds down, you could almost throw darts at these standout groups -- but here are my own picks.
Nov 25, 2014 | 7:40 AM EST
BMRN price target raised to $100 from $87, said Jefferies. Favorable view following acquisition of Prosensa. Buy rating remains.
Nov 03, 2014 | 7:57 AM EST
BMRN was upgraded from Market Perform to Outperform, Wells Fargo said. Company has multiple potential clinical catalysts in 2015.

Resistance Is Futile Real Money Pro($)

Here are three stock that have returned to former breakout levels.
Use the oversold bounces for trimming, cutting or hedging positions.
The focus is on all things momentum.

Columnist Conversations

Kulicke & Soffa(+7%)is in full breakout mode today. The stock opened with an upside gap that pushed ...
Seemed as if comments related to inflation were a table setter in pushing out the first rate increase until th...
While many are concerned about a negative reaction if the Fed doesn't hint at pushing out interest rate hikes ...
We are nearly to the Fed decision and this time around expectations for what's to come are rather muted. No m...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.